Division of General Internal Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.
Institute of HIV/AIDS Disease Prevention and Control, Rwanda Biomedical Center, Kigali, Rwanda.
J Int AIDS Soc. 2020 Jun;23(6):e25543. doi: 10.1002/jia2.25543.
Aiming to reach UNAIDS 90-90-90 targets, nearly all sub-Saharan African countries have expanded antiretroviral therapy (ART) to all people living with HIV (PLWH) (Treat All). Few published data exist on viral load testing and viral suppression under Treat All in this region. We assessed proportions of patients with available viral load test results and who were virally suppressed, as well as factors associated with viral suppression, among PLWH in 10 Rwandan health centres after Treat All implementation.
Cross-sectional study during 2018 of adults (≥15 years) engaged in HIV care at 10 Rwandan health centres. Outcomes were being on ART (available ART initiation date in the study database, with no ART discontinuation prior to 1 January 2018), retained on ART (≥2 post-ART health centre visits ≥90 days apart during 2018), available viral load test results (viral load measured in 2018 and available in study database) and virally suppressed (most recent 2018 viral load <200 copies/mL). We used modified Poisson regression models accounting for clustering by health centre to determine factors associated with being virally suppressed.
Of 12,238 patients, 7050 (58%) were female and 1028 (8%) were aged 15 to 24 years. Nearly all patients (11,933; 97%) were on ART, of whom 11,198 (94%) were retained on ART. Among patients retained on ART, 10,200 (91%) had available viral load results; of these 9331 (91%) were virally suppressed. Viral suppression was less likely among patients aged 15 to 24 compared to >49 years (adjusted prevalence ratio (aPR): 0.83, 95% CI 0.76 to 0.90 and those with pre-ART CD4 counts of <200 compared to ≥500 cells/mm (aPR: 0.92, 95% CI 0.90 to 0.93). There was no statistically significant difference in viral suppression among patients who entered after Treat All implementation compared to those who enrolled before 2010 (aPR 0.98, 95% CI 0.94 to 1.03).
In this large cohort of Rwandan PLWH receiving HIV care after Treat All implementation, patients in study health centres have surpassed the third UNAIDS 90-90-90 target. To ensure all PLWH fully benefit from ART, additional efforts should focus on improving ART adherence among younger persons.
为了实现联合国艾滋病规划署的 90-90-90 目标,几乎所有撒哈拉以南非洲国家都将抗逆转录病毒疗法(ART)扩大到所有艾滋病毒感染者(PLWH)(治疗所有)。在该地区,关于治疗所有方案下的病毒载量检测和病毒抑制的已发表数据很少。我们评估了在治疗所有方案实施后,10 个卢旺达卫生中心接受 HIV 护理的 PLWH 中,有多少患者可获得病毒载量检测结果和病毒抑制情况,以及与病毒抑制相关的因素。
2018 年在卢旺达 10 个卫生中心进行的成年人(≥15 岁)参与 HIV 护理的横断面研究。研究结果为正在接受 ART(研究数据库中存在可用的 ART 起始日期,并且在 2018 年 1 月 1 日之前没有停止 ART)、接受 ART 保留治疗(2018 年期间至少有 2 次在 ART 后卫生中心就诊,两次就诊间隔≥90 天)、可获得病毒载量检测结果(2018 年测量的病毒载量并在研究数据库中可用)和病毒抑制(最近的 2018 年病毒载量<200 拷贝/毫升)。我们使用修正泊松回归模型,根据卫生中心进行聚类,以确定与病毒抑制相关的因素。
在 12238 名患者中,有 7050 名(58%)为女性,1028 名(8%)年龄在 15 至 24 岁之间。几乎所有患者(11933 名;97%)都在接受 ART,其中 11198 名(94%)接受了 ART 保留治疗。在接受 ART 保留治疗的患者中,有 10200 名(91%)可获得病毒载量结果;其中 9331 名(91%)病毒得到抑制。与年龄在 49 岁以上的患者相比,年龄在 15 至 24 岁的患者病毒抑制的可能性较小(调整后的患病率比(aPR):0.83,95%CI 0.76 至 0.90 和 CD4 计数在治疗前低于 200 个细胞/mm 与≥500 个细胞/mm 的患者相比(aPR:0.92,95%CI 0.90 至 0.93)。与 2010 年前入组的患者相比,在治疗所有方案实施后入组的患者的病毒抑制率没有统计学上的显著差异(aPR 0.98,95%CI 0.94 至 1.03)。
在这项对接受治疗所有方案后接受 HIV 护理的大量卢旺达 PLWH 的研究中,研究中心的患者已经超过了联合国艾滋病规划署的第三个 90-90-90 目标。为了确保所有 PLWH 都能从 ART 中充分受益,应进一步努力提高年轻人的 ART 依从性。